IAP antagonists are a class of compounds that were developed to induce cancer cell death by blocking the caspase inhibitory function of the IAP protein XIAP, but were found to bind with tenfold higher affinity to the cellular IAPs cIAP1 and cIAP2 (ref. 1). cIAP1 and cIAP2 do not bind directly to caspases, but instead promote cell survival via E3-mediated ubiquitination of target proteins, leading to activation of the NF-κB pathway 1 . The IAP antagonist LCL161 is a small molecule that binds with high affinity to the BIR3 domains of cIAP1, triggering its auto-ubiquitination and proteolysis, resulting in a pulse of NF-κB signaling and a rise in TNF production. In the absence of cIAP1, TNF signaling triggers the induction of a RIPK1-FADD-caspase 8 apoptotic complex or, in the absence of caspase 8, necroptotic cell death [1] [2] [3] [4] . Preclinical data indicate that LCL161 has only modest activity in the absence of TNF, but synergizes with other chemotherapeutics in various tumor models, most likely by lowering the threshold for TNF-dependent apoptotic cell death [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] . LCL161 has been evaluated in a phase 1 clinical trial (ClinicalTrial.gov, NCT01098838) in patients with advanced solid tumors of lung, skin, colon, pancreas and other 16 . cIAP1 degradation was observed in paired pre-and post-treatment tumor biopsies at an oral weekly dose of 900 mg. The dose-limiting toxicity was cytokine release syndrome concurrent with the rapid increase in plasma cytokine levels of TNF, interleukin (IL)-8, IL-10 and the monocyte chemoattractant protein-1 (MCP1). This inflammatory reaction is not surprising, given that we and others have found that, in addition to being positive regulators of the NF-κB pathway, cIAP1 and cIAP2 are also negative regulators of the noncanonical NF-κB pathway, which is crucial for the modulation of innate and adaptive immunity by promoting cytokine production 2, 3, [17] [18] [19] [20] . Noncanonical NF-κB activation requires proteasomal-mediated partial degradation of the inactive NF-κB2 p100 to its active p52 form, which is initiated when it is phosphorlyated by the NF-κB-inducing kinases NIK and IKK-α. In the absence of stimuli, NIK exists in a cytoplasmic complex with the TNF receptor-associated factor 3 (TRAF3) cIAP1 and cIAP2, where it is rapidly ubiquitinated and degraded 1 . Following the binding of ligands such as CD40L or BAFF to their receptors, the TNF receptor-associated factor 3 (TRAF3), cIAP1 and cIAP2 are recruited to the cell membrane, releasing NIK, which phosphorylates IKK-α and NFkB2, leading to p100 to p52 processing, as well as IKK-β, which induces NFKB1 p50 activation 21 . Thus, by inducing the degradation of cIAP1 and cIAP2, the release of NIK and the activation of NFkB2, LCL161 induces co-stimulatory activity in human peripheral blood T cells by enhancing cytokine secretion, and mimics CD40L by inducing dendritic cell (DC) maturation [22] [23] [24] .
A dual role for cIAP1 and cIAP2 in tumorigenesis has been observed through the analysis of multiple data sets from The Cancer
The cellular inhibitors of apoptosis (cIAP) 1 and 2 are amplified in about 3% of cancers and have been identified in multiple malignancies as being potential therapeutic targets as a result of their role in the evasion of apoptosis. Consequently, smallmolecule IAP antagonists, such as LCL161, have entered clinical trials for their ability to induce tumor necrosis factor (TNF)-mediated apoptosis of cancer cells. However, cIAP1 and cIAP2 are recurrently homozygously deleted in multiple myeloma (MM), resulting in constitutive activation of the noncanonical nuclear factor (NF)-kB pathway. To our surprise, we observed robust in vivo anti-myeloma activity of LCL161 in a transgenic myeloma mouse model and in patients with relapsed-refractory MM, where the addition of cyclophosphamide resulted in a median progression-free-survival of 10 months. This effect was not a result of direct induction of tumor cell death, but rather of upregulation of tumor-cell-autonomous type I interferon (IFN) signaling and a strong inflammatory response that resulted in the activation of macrophages and dendritic cells, leading to phagocytosis of tumor cells. Treatment of a MM mouse model with LCL161 established long-term anti-tumor protection and induced regression in a fraction of the mice. Notably, combination of LCL161 with the immune-checkpoint inhibitor anti-PD1 was curative in all of the treated mice. a r t i c l e s 1 4 1 2 VOLUME 22 | NUMBER 12 | DECEMBER 2016 nature medicine Genome Atlas (TCGA) for copy-number abnormalities of BIRC2 and BIRC3, the genes encoding cIAP1 and cIAP2 (refs. 25,26) : highamplification levels are seen in several cancer types (cervical 11%, ovarian 7%, head and neck 6%, bladder 4%), whereas deletions are seen in others (testicular 4%, diffuse large B-cell lymphoma 2%, breast 1%). In MM, we and others have reported frequent biallelic inactivation of cIAP1, cIAP2, TRAF2 and TRAF3 (ubiquitination targets of cIAP1 and cIAP2), and amplification or translocation of NIK 17, 19 , affecting approximately 15% of the MM patients enrolled in the COMMpass project (http://research.themmrf.org). Given that it has been shown that genetic or pharmacological disruption of cIAP1 and cIAP2 in murine B lymphocytes renders them independent of BAFF for survival and induces uncontrolled proliferation 27, 28 , we speculated that cIAP1 and cIAP2 blockade might enable MM growth independently of intra-medullary secreted TNF family ligands (that is, BAFF and APRIL), allowing extra-medullary dissemination. Having modeled the NF-κB2-activating effects of biallelic deletion of cIAP1 and cIAP2 in MM using IAP antagonist in vitro 18, 21 , we set out to examine the in vivo effects by treating Vk*MYC mice 29 with LCL161. The immunocompetent Vk*MYC transgenic mouse model is characterized by sporadic AID-dependent activation of MYC in germinal center B cells, leading to progressive accumulation of monoclonal plasma cells in the bone marrow. To our surprise, we found that, instead of promoting MM growth, LCL161 modulated the MM tumor milieu to induce a potent immune activation that invoked anti-tumor phagocytic activity and long-lasting anti-tumor immunity.
RESULTS

LCL161 exhibits potent preclinical anti-myeloma activity
Treatment of human MM cell lines (HMCLs) that do not harbor NF-κB-activating mutations with LCL161 induced p100 to p52 processing, a marker of noncanonical NF-κB activation ( Supplementary Fig.  1a ) 21 . In contrast with the direct cytotoxic effects of IAP antagonists in other models 2, 4, 16, [30] [31] [32] , LCL161 did not induce cell death in our experimental system. We only observed cell killing at doses exceeding those achieved clinically 16 , even in KMS28PE cells, which harbor biallelic deletion of cIAP1 and cIAP2, indicating that killing was likely a result of off-target effects of LCL161 (refs. 33,34) . Consistent with TNF having a strong pro-survival role in MM mediated by NF-κB activation 35 , but in contrast with the pro-apoptotic effects of TNF in combination with IAP antagonists that have been reported in other pre-clinical models [2] [3] [4] 9, 13 , the addition of exogenous TNF neither potentiated LCL161 activity nor induced cell death in HMCLs in vitro, but instead rescued the lethality observed at nonclinically relevant concentrations of the drug (Supplementary Fig. 1b) . Next, we studied the effects of LCL161 in vivo. We exposed aged Vk*MYC transgenic mice with established MM to a well-tolerated dose of LCL161, as determined by previous in vivo studies [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] . In contrast to our expectation of observing induction of extra-medullary dissemination of MM, the quantification of the M-spike, the serum monoclonal immunoglobulins produced by the myeloma plasma cells, revealed a reduction in tumor burden that was comparable to that observed in response to standard-of-care agents in MM: the proteasome inhibitors carfilzomib and bortezomib (BOR), the DNA alkylators melphalan (MEL) and cyclophosphamide (Cy), the histone deacetylase inhibitor panobinostat, dexamethasone (DEX) and the immunomodulatory drug (IMiD) pomalidomide (Fig. 1a) . We have previously validated the Vk*MYC transgenic mouse as a useful model for predicting drug activity in MM 36 , with an updated positive predictive value for clinical activity of 73% and a negative predictive value of 92% (Supplementary Fig. 2) . Thus, the single-agent activity of LCL161 that we observed in Vk*MYC mice underscored its value as a promising anti-MM agent 36 . LCL161 was also active against the aggressive, BOR-resistant Vk12598 transplantable MM cell line derived from Vk*MYC mice, which lacks NF-κB-activating mutations (Fig. 1b) , but was inactive against the multidrug refractory Vk12653 MM cell line, which carries an NF-κB-activating mutation 36 (Fig. 1c) . Among standard-of-care agents with direct anti-MM activity, Cy, which has been reported to potentiate adaptive immune responses against established tumors by abrogating regulatory T cells (T reg cells) and to induce an acute secretory-activating phenotype that promotes macrophage (MΦ) infiltration and phagocytosis of tumor cells 37, 38 , and panobinostat, which is known to enhance tumor cell immunogenicity by increasing the expression of MHC and co-stimulatory molecules 39 , synergized with LCL161 to reduce M-spike levels in Vk12653-tumor-bearing mice. By contrast, we observed no synergism between LCL161 and the immune-suppressive agents BOR or DEX, both of which antagonized LCL161 activity in Vk12598 MM cells (Fig. 1b,c) . Furthermore, we noted no M-spike reduction when we combined LCL161 and the Toll-like-receptor 3 activator poly(I:C) ( Supplementary  Fig. 3a,b) . Finally, LCL161 prolonged survival in two syngeneic Balb/c plasmacytoma murine models of MM ( Supplementary Fig. 3c,d) .
Pretreatment in vivo with anti-TNF blocking antibody 1 day before LCL161 dosing partially inhibited LCL161 activity against Vk12598 MM, as did an antibody against IL-12, suggesting that the inflammatory activity of TNF and IL-12 might contribute to the in vivo anti-MM activity of LCL161 (Fig. 1d) . Exposure of Vk12598 cells in vitro to LCL161 did not induce cell death or the expression of apoptotic markers, as compared with vehicle-treated controls ( Supplementary  Fig. 4) . Furthermore, histological examination of Vk*MYC tumor sections from BOR-or LCL161-treated mice showed cleaved-caspase 3 staining only in the former, and evidence of phagocytosis of intact MM cells only in the latter (Fig. 1e) .
These data indicate that LCL161 was not directly cytotoxic to MM cells in vitro, where it induced activation of the noncanonical NF-κB pathway, mimicking the effects of biallelic cIAP1 and cIAP2 inactivation that have been observed in patients with MM. However, LCL161 exhibited anti-MM activity in vivo in a clinically predictive model, which was independent of caspase-3-mediated apoptosis, but was instead a result of phagocytosis of non apoptotic cells. We therefore sought to evaluate LCL161 treatment in patients with MM.
Durable anti-myeloma activity of LCL161 in MM patients
We initiated a phase 2 clinical trial of LCL161 in relapsed-refractory MM (ClinicalTrials.gov, NCT01955434). As part of the original trial design, we planned for the addition of Cy in the event of disease progression, or following a lack of response, after 8 weeks of LCL161 single agent. A response is defined by the International Myeloma Working Group Uniform Response Criteria for Multiple Myeloma as a 50% reduction of paraprotein (the monoclonal immunoglobulin secreted by myeloma cells) in the serum or urine 40 . Among the 25 patients treated with LCL161, the median number of prior therapies was three, 44% of the patients had high-risk features and 72% of the patients had refractory disease progressing on therapy (Supplementary Table 1) . Because of grade 2 cytokine release syndrome in 4 of the first 11 patients treated at 1,800 mg orally weekly (Supplementary Table 2) , we elected to lower the dose of LCL161 to 1,200 mg rather than adding prophylactic DEX, given our data of in vivo antagonistic activity between DEX and LCL161 in our preclinical models. 500 mg of weekly oral Cy was added in 23 of the 25 patients that continued © 2016 Nature America, Inc., part of Springer Nature. All rights reserved. a r t i c l e s nature medicine VOLUME 22 | NUMBER 12 | DECEMBER 2016 1 4 1 3 the study. Although there were no responses to single-agent LCL161, responses were seen following the addition of Cy in five patients (1CR, 1 VGPR, 2 PR, 1 MR), with median progression-free-survival (PFS) of 10 months (Fig. 2a,b) . The depth and duration of the response can best be seen by examining the course of individual patients. Patient 1, following a transient response to LCL161 single agent, achieved immunofixation negative complete response (CR) after the addition of Cy (Fig. 2c) . Patient 2 received 12 weeks of LCL161, the last four of which were in combination with Cy and stopped treatment because of concerns of undocumented progressive disease. He achieved a partial response (PR) and long-term disease control with immune reconstitution, as evidenced by a rise of his uninvolved IgG to the normal range.
He remains with stable disease with 5% bone marrow (BM) plasma cells (BMPC) (down from 40% before treatment) 27 months after stopping treatment, the longest period of time he has been off therapy since his diagnosis with MM (Fig. 2d) . Patient 3 obtained a very good partial response (VGPR) following the addition of Cy to LCL161, but progressed 14 months after starting the treatment (Fig. 2e) . Patient 4 achieved a PR following the addition of Cy to LCL161, progressing 25 months after starting the treatment (Fig. 2f) .
MM cell-autonomous type I interferon is required for the anti-MM activity of LCL161 in vivo RNA-seq analysis of purified MM cells from mice treated overnight with vehicle or LCL161, or MM cells collected from five patients with MM before and after 3-4 weeks of LCL161 single-agent treatment, revealed a marked upregulation of NF-κB target genes that was consistent with the processing of p100 observed in vitro and with a type I interferon (IFN) signature ( Fig. 3a and Supplementary Table 3) . Notably, although this signature was evident in the LCL161-responsive Vk12598 mice and in all five patients with MM whom we analyzed, it was not detected in the LCL161 refractory Vk12653 mice, where, instead, we noted constitutively high baseline expression of NF-κB target genes that was not further enhanced by LCL161 treatment. We suspect that this is a result of a high level of ectopic initiation of transcription of MAP3K14 (NIK) from an intra-cisternal A particle long-terminal repeat, which likely results from retrotransposition 41 , and mimics the dysregulation of NIK observed in MM samples as a result of chromosome translocation 17 ( Supplementary Fig. 5 ). Gene set enrichment analysis performed on the most upregulated genes in both mice and patients identified gene sets corresponding to IFN response, inflammation and NF-κB activation (Fig. 3b) , which we confirmed to be a direct effect of LCL161 treatment in vitro in a Balb/c plasmacytoma cell line (Supplementary Fig. 6 ). A type-I IFN signature in cancer cells is required for the therapeutic efficacy of certain chemotherapeutic agents and has been linked to the anti-tumor properties of LCL161, as demonstrated by the synergism between LCL161 and oncolytic virus infection in pre-clinical murine models 31, [42] [43] [44] . We therefore assessed the contribution of IFN signaling to the anti-MM activity of LCL161 in vivo. We found that blocking type-I IFN signaling on both tumor and host cells with an antibody specific for the IFN-α/b receptor subunit 1 (aIFNAR1) was sufficient to abrogate the LCL161-induced survival advantage in Vk12598-tumor-bearing mice (Fig. 3c) . In apparent contrast, when we engrafted Vk12598 MM cells into recipients, either IRF3/IRF7 null mice, which do not express type I IFN, or IFNAR null mice, which do not respond to IFN signaling, LCL161 retained its anti-MM activity, implicating MM cell-autonomous IFN signaling in LCL161 activity (Fig. 3d) . These data suggest that type-I IFN produced by tumor cells, recapitulating a viral infection, induces an inflammatory reaction that ultimately leads to tumor cell phagocytosis. We therefore sought to investigate the effects of LCL161 treatment on myeloid cells.
LCL161 treatment induces an acute inflammatory response and activates phagocytic cells MΦ and DCs become activated in response to CD40 ligation, which, similarly to LCL161, leads to activation of NF-κB2. We therefore examined the effects of LCL161 treatment on these cells. Consistent with published data 24, 45 , we found that LCL161 treatment induced expression of CD11b and the maturation marker CD86 in murine BM-derived DCs generated in vitro, where it also upregulated expression of the inflammatory proteins TNF, IL-6, IL-12b, IFN-β and NOS2 ( Fig. 4a and Supplementary Fig. 7 ). We noted a similar inflammatory response, characteristic of M1-polarized MΦ, in LCL161-treated BMderived MΦ (BMDMs) that was further potentiated by IFN-γ priming (Fig. 4b) . In vivo, LCL161 induced expression of CD86 on DCs and CD40 on MΦ from wild-type (WT) and Vk12598-tumor-bearing mice, concomitant with upregulation of IL-12 and IL23p40 and iNOS expression ( Fig. 4c-f) . Notably, such activation was not noted in mice engrafted with the LCL161-resistant Vk12653 line, indicating the presence of an immunosuppressed microenvironment. The addition of Cy overcame this immunosuppression, most likely by promoting an acute secretory-activating phenotype on tumor cells 38 , and further increased the expression of activation markers in Vk12598-tumorbearing mice (Fig. 4g,h) . Consistent with the immunophenotyping data, we observed upregulation of inflammatory cytokines following LCL161 treatment in the BM from WT and Vk12598, but not in Vk12653, tumor-bearing mice (Fig. 4i) . We also detected a similar induction of inflammatory cytokines in the BM plasma from patients with MM collected 3 weeks after they were given their first dose of LCL161 (Fig. 4j) . These cytokine profiles have been associated with successful immune-mediated cancer eradication and immunosurveillance in mouse studies 46 . As reported in the phase 1 study of LCL161 in solid tumors 16 , acute changes of IL-8, IL-12 and MCP1 cytokine levels were also noted in peripheral blood 4 h posttreatment, although changes in TNF were not documented ( Supplementary Fig. 8 ). We conclude that LCL161-mediated NF-κB activation, mimicking CD40 engagement, is directly responsible for inducing an inflammatory response in MΦ and DCs in vitro, which is further potentiated in vivo by the presence of LCL161-sensitive tumor cells.
LCL161 treatment stimulates myeloma cell secretion of soluble factors that induce tumor cell phagocytosis by M
We next sought to determine whether LCL161 treatment affects the ability of MΦ to phagocytize tumor cells in the presence or absence of cancer-cell-autonomous IFN signaling. Vk*MYC MM cells and transplantable cell lines do not survive in vitro, so we used a Vk*MYC-derived B cell lymphoma (Vk26963) line as the target cells 29 , which are fully resistant to LCL161 treatment. Activation of BMDM with LCL161 in vitro did not increase phagocytosis, and the combination of LCL161 and IFN-γ did not show any differences in the uptake of untreated Vk26963 target cells as compared with IFN-γ alone (Fig. 5a ). However, pretreatment of target cells with LCL161, without inducing phosphatidylserine or calreticulin cell surface expression or altering CD47 levels, resulted in significantly higher uptake by IFN-γ-primed BMDMs than vehicletreated Vk26963 cells (Supplementary Fig. 9 ). Furthermore, the incubation of BMDMs with conditioned medium collected after LCL161 treatment of Vk26963 cells increased the uptake of untreated target cells. Pre-treatment of Vk26963 cells with aIFNAR blocking antibody, but not isotype control, inhibited this effect; conditioned medium collected after aIFNAR + LCL161 treatment did not induce phagocytosis above baseline levels (Fig. 5b) . We conclude that LCL161 treatment induces a type-I IFN response in tumor cells, promoting the release of soluble factor(s) that stimulate their phagocytosis by BMDMs. To confirm the in vitro phagocytic studies, we performed in vivo imaging of GFPlabeled Vk*MYC cells in the tibia BM using two-photon microscopy. After LCL161 treatment, imaging revealed an increase of phycoerythrin (PE)-labeled phagocytic cells in the GFP + myeloma foci ( Fig. 5c-e) , with increased phagocytic activity, as measured by increased frequency of GFP + PE + phagocytes ( Fig. 5f ). Time-lapse intra-vital imaging confirmed phagocytosis of intact MM cells, in real-time, as early as 4 h after treatment (Supplementary Videos 1 and 2). Finally, pre-treatment of Vk12598-tumor-bearing mice with liposomal clodronate, which is known to cause depletion of phagocytes, 1 d before LCL161 administration significantly reduced LCL161 activity and abolished the survival advantage induced by LCL161, indicating that MΦ-dependent phagocytosis is required for the in vivo anti-MM effects of LCL161 (Fig. 5g ). We conclude that LCL161 treatment induces an IFN response in MM cells that promotes recruitment of phagocytes to the tumor microenvironment and increases their ability to phagocytize tumor cells.
Adaptive immunity is essential for long-term disease control, but is dispensable for the initial response to LCL161 The potential of IAP antagonists to enhance murine and human CD8 and CD4 T-cell function by increasing the expression of surface markers for activating (CD25) and promoting IL-2 and IFN-γ cytokine production has been investigated previously in in vitro studies 22 . We therefore sought to investigate the effects of LCL161 treatment on T cell activation in vivo. LCL161 induced an increase in CD25 expression on CD4 + T cells from Vk12598-tumor-bearing mice compared with controls ( Supplementary Fig. 10a) . However, the numbers of CD4 + and CD8 + T cell effectors and of IFN-γ-producing cells were not increased ( Supplementary Fig. 10b-e) . Given the lack of T-cell activation, it was not surprising that the response to LCL161 was similar in CD4 + , CD8 + and NK1.1 + cell-depleted and IgG-treated control mice ( Supplementary  Fig. 10f ). In a complementary approach, we transplanted Vk12598 MM cells into WT or RAG1 null recipient mice. LCL161 induced a similar response in both sets of recipient mice, where it also prolonged overall survival ( Fig. 6a and Supplementary Fig. 10g) . Notably, although the median survival of mice receiving vehicle was only ~10 d, 2 weeks of LCL161 treatment was curative in ~15% of the Vk12598-tumor-bearing WT mice, whereas it was curative in none of the RAG1 null mice, suggesting that adaptive immunity is dispensable for the short-term anti-MM effect of LCL161, but is necessary to prevent disease recurrence. Clonal expansion of tumor-specific T cells, protection against tumor recurrence and production of T H 1 cytokines are all hallmarks defining immunological memory that contribute to protection against tumor recurrence. We investigated the capability of the immune response to reject tumor re-challenge in Vk12598 mice that had remained tumorfree 1 year after treatment with LCL161. The recurrence of MM was prevented in 66% (four of six) of the mice, which remained tumor free until they were killed 4 months later (data not shown). Next, we characterized MM-specific memory T cell generation in Vk12598 mice that were cured by LCL161 by inoculation with a secondary challenge of either the same (Vk12598) or an irrelevant (Vk26633) tumor. Immunological memory characterized 7 d later revealed a robust expansion in CD4 + , but not CD8 + , effectors (CD44 hi CD62L lo ) and memory (CD44 hi CD62L hi ) T cells, and a corresponding increase in IFN-γ-producing CD4 + T cells (Fig. 6b-d ) in response to MM cells, as compared with the irrelevant tumor. This lack of CD8 + T cell expansion was surprising, and prompted us to assess the expression of CD25, given that numerous studies have reported that downregulation of CD25 on CD8 + T cells affects primary and secondary memory expansion following tumor challenge 47, 48 . Vehicle n = 75 IFIT3  CD40  ANXA2  GBP2  CFB  TNFAIP3  NFKBIE  IL2RG  IRF7  ICAM1  RELB  LGALS3  AHNAK  GBP5  NFKBIA  NFKB2  IKBKE  PARP14  TUBA1A  EGR1  BIRC3  RNF19B  BCL3  ISG15  STX11  UBE2L6  GBP3  SAT1  PIM1  TMEM106A  HSPB1 Gene set enrichment analysis using the list of 384 upregulated genes common to mice and human MM treated with LCL161 in vivo in the HALLMARK gene sets. The observed enrichment score (ES) of a gene set was generated using a running-sum statistic along the ranked differential expression genes, where ES is the maximum deviation from zero encountered in the random walk. A phenotype-based permutation test was performed to generate a null distribution of the ES, and the empirical, nominal P value of a gene set was calculated as the observed ES relative to this null distribution. ES, enrichment score; NES, normalized enrichment score; FDR, false-discovery rate; FWER, family-wise error rate. Consistently, no CD25 + CD8 + T cells were detected, irrespective of treatment or tumor re-challenge, in Vk12598-tumor-bearing mice (Fig. 6e) . We conclude that LCL161 promotes long-term MM control in a fraction of mice through the generation of immunological memory.
Combination of LCL161 and anti-PD1 cures myeloma in mice
It is likely that the hypo-responsiveness of T cells to initial LCL161 activation is a result of an expansion of T reg cells and/or because the T cells have become refractory and exhausted after exposure to chronic antigenic stimulation associated with the MM microenvironment. We compared and detected a similarly low percentage (1-3%) of CD4 + CD25 + FOXP3 + T reg cells in the spleens from Vk12598-tumorbearing versus non-tumor-bearing mice, with similar levels of coinhibitory molecule PD-1 surface expression (Fig. 6f,g and data not shown). However, the expression of co-inhibitory molecule PD-1 on CD4 effector (CD44 hi CD62L lo ) T cells (Fig. 6g,h) , as well as effector CD8 + T cells (Fig. 6i) , was markedly elevated, with no changes being induced by treatment. We next evaluated the expression of the PD-1 ligand PD-L1 in the MM tumor milieu. Nearly all of the CD11b + myeloid cells expressed PD-L1 (Fig. 6j) , as compared with only a fraction of Vk12598 MM cells. However, PD-L1 expression was significantly increased following in vivo treatment with LCL161 (Fig.  6k) . Notably, this effect was not observed in MM cell lines treated in vitro ( Supplementary Fig. 11a-e) . These findings prompted us to combine LCL161 with an antibody against PD-1. In an experiment in Vk12598-tumor-bearing mice, in which the median survival of control mice was only 7 d, PD-1 antibody doubled the survival to 14 d and LCL161 further increased it to 33 d. The combination of LCL161 and anti-PD-1 was curative in all of the mice that completed 2 weeks of treatment, immediately abrogating the early mortality observed in the other conditions, and was more effective than the combination of LCL161 with Cy, where the median survival was 84 d (Fig. 6l) . [52] [53] [54] [55] . We found that single-agent LCL161 induced a marked anti-MM response in Vk*MYC mice that was not a result of direct cell killing, but rather of activation of a tumor-cellautonomous type-I IFN signaling, leading to myeloid cell activation and tumor cell phagocytosis. Consistently, we observed no in vivo anti-MM response to LCL161 following phagocytic cell depletion. Treatment of MΦ with LCL161 in vitro, although it induced activation, did not increase their phagocytic ability, which in contrast was augmented by soluble factors released by treated tumor cells. IFN signaling in tumor, but not host, cells is essential for promoting phagocytosis, because it was prevented by blocking the type-I IFN receptor on tumor cells.
DISCUSSION
There is an apparent paradox between the anti-tumor activity of LCL161 that we observed in vivo and the fact that clonal progression in MM frequently selected for elimination of cIAP1 and cIAP2, the targets of IAP antagonists, presumably to benefit from the survival advantage deriving from chronic NF-κB activation. On one hand, the depletion of cIAP1 and cIAP2 in tumor cells by LCL161 treatment induced a type-I IFN signaling, a characteristic of viral mimicry, that stimulates endogenous immunity to eradicate MM. At the same time, the loss of cIAP1 and cIAP2 in the host immune cells leads to NF-κB activation, causing an inflammatory reaction that further potentiates the host immune response against the tumor. Furthermore, NF-κB activation has been shown to provide a strong survival signal that protects cells from the pro-apoptotic activity of TNF 56 . MM cells were characterized by a liganddependent activation of the non canonical NF-κB pathway, mediated by BAFF and APRIL, which was also induced by IAP antagonist treatment.
We speculate that this explains why treatment with IAP antagonist failed to promote TNF-dependent apoptosis in other tumor types.
No single-agent LCL161 activity was observed in the Vk12653 transplantable model carrying an activating mutation of the non canonical NF-κB pathway and a tumor microenvironment that was markedly suppressed for myeloid cell activation. No tumor induction of NF-κB or IFN response was noted in this model following LCL161 treatment, and we did not observe changes in inflammatory cytokines, consistent with our findings that blocking either the IFN response or the TNF or IL-12 inflammatory pathways abrogated the response of MM cells to LCL161. Although the cause of immunosuppression in Vk12653 mice is presently unknown, the addition of Cy to LCL161 resulted in significant DC activation and anti-MM response, most likely by promoting direct tumor cell killing. LCL161 also did not demonstrate single-agent activity in MM patients, despite the induction of an NF-κB and IFN response on MM cells and the detection of inflammatory cytokines in the BM serum, suggesting the presence of a LCL161-sensitive immune microenvironment. We suspect that differences in the immune microenvironment between mice with de novo or transplanted MM, and heavily pretreated, multiply relapsed patients might explain the differential responses to single-agent LCL161 treatment observed in mouse and MM patients. Following the addition of Cy, however, we noted durable disease control with a median PFS of 10 months in this cohort of patients with relapsed-refractory MM, accompanied by evidence of immune reconstitution (increase levels of uninvolved Ig). This PFS was greater than one would expect for single-agent Cy in this patient population, given that the two-drug combination of MEL and prednisone only induces a PFS of 12-13 months in the much more responsive patient population of untreated MM 57, 58 . By contrast, in an only slightly more refractory population (median four prior lines), the three-drug combination of Cy, pomalidomide and DEX results in a median PFS of 9.5 months 59 . In summary, the combination of LCL161 and Cy is a well-tolerated oral regimen that offers long-term disease control in relapsed-refractory MM that is immuno-stimulatory and does not expose patients to the immunosuppressive effects of a glucocorticoid. We were surprised that adaptive immunity was dispensable for the initial anti-MM response to LCL161. Although we observed increased CD25 expression, a marker of early activation, on CD4 + T cells following LCL161 treatment, most of the effector T cells expressed PD1, and presumably, became anergic in the MM tumor milieu that abundantly expressed PD-L1. Notably, however, a fraction of mice were cured in response to 2 weeks of treatment with LCL161, indicating effective immune surveillance, as demonstrated by the development of immunological memory. Promoting sustained T cell activation with anti-PD1 had an immediate effect on the LCL161-induced anti-MM response, resulting in a notable cure. We conclude that the combination of LCL161 and Cy is an attractive platform for future trials of anti-tumor immune activation in MM, and in combination with anti-PD1.
METHODS
Methods and any associated references are available in the online version of the paper.
Accession codes. The FASTQ files of the RNA-Seq data were submitted to Sequence Read Archive under accession number SRP075564. 
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AUtHoR CoNtRIBUtIoNS
ONLINE METHODS
Cell lines and reagents. Human MM cell lines have been previously described 17 and have been maintained in RPMI 1640 supplemented with 5% FBS and glutamine, without antibiotics. The XRPC24 (ref. 60 ) and J558 Balb/c plasmacytoma cell lines were kindly donated by M. Kuehl (NIH-NCI) and were grown in RPMI + 5% FBS supplemented with glutamine, penicillin, streptomycin and 50 µM β-mercapto-ethanol (mouse medium). None of these lines are listed on the ICLAC database of commonly misidentified cell lines and are routinely fingerprinted by assessment of copy-number polymorphisms by PCR. The Vk26963 B cell lymphoma and the Vk26633 thymic T-cell lymphoma cell lines were generated by culturing splenocytes of aged Vk*MYC transgenic mouse with lymphoma and were maintained in mouse medium 29 . L929 cells were purchased from ATCC. All cell lines are tested for mycoplasma contamination twice per year using the MycoAlert kit (Promega). LCL161 was provided by Novartis and solubilized at 1 mM in DMSO for in vitro studies or at 10 mg/ml in 30% HCl 0.1N + 70% Sodium acetate 100 mM pH = 4.5 for in vivo administration. Recombinant human TNF was purchased from R&D System. Recombinant murine IFN-γ is from Pepro Tech. Anti-TNF blocking antibody (clone CNTO-5048) was a gift of Centocor. Anti-IL-12 P40 (C17.8), anti-IFNAR (MAR1-5A3) and anti-PD1 (RMP1-14) were obtained from BioXCell, together with mouse IgG1 or ratIgG2a isotype controls. Anti-CD4 (GK1.5), anti-CD8 (2.43), anti-NK1.1 (PK136) and their isotype controls were obtained from Leinco Technologies. Clodronate and PBS liposomal particles were purchased from ClodronateLiposomes.com. HMW poly(I:C) was purchased from Invivogen. Annexin-V and propidium iodine (PI) were purchased from BD Biosciences. In vivo drug administration. At least three aged (>70 weeks old) de novo Vk*MYC mice of any sex, with a γ/albumin ratio between 0.5-2.0 corresponding to a predominant M-spike between approximately 15-60 g/l were treated with each drug 64 . Transplanted mice were enrolled in the studies approximately four weeks post-transplantation, with M-spike levels >10 g/l, or a γ/albumin fraction >0.3 to mimic clinical setting. Mice were randomized to different treatment arms, stratified by the size of their M-spikes. Standard-of-care drug dosage and route of administration has been already reported 36 . LCL161 (Novartis) was solubilized at 10mg/ml in 30% HCl 0.1N + 70% sodium acetate 100 mM pH = 4.5 and given by oral gavage at 50 or 100 mg/kg on days 1, 4, 8 and 11. Cyclophosphamide (Sigma) was solubilized in saline and administered by i.p. injection at 100mg/kg on days 1 and 8. Antibodies were diluted at 1 mg/ml in PBS and administered by i.p. injection at 10 mg/kg at the specified days. 200 µl of liposomal particles containing PBS or 5m g/ml clodronate were administered i.v. on days 0, 3, 7 and 10 followed by LCL161 at 50 mg/kg p.o. on days 1, 4, 8 and 11.
Poly(I:C) was given at 2.5 mg/kg by i.p. injection on days 1, 4, 8 and 11. SPEP at day 0 and day 14 post-treatment was performed to measure reduction in the M-spike as a marker of tumor response, as done clinically. Specifically, the gamma/albumin ratio post-treatment for each individual M-spike is calculated while remaining blinded to the treatment allocation group and then is normalized by the gamma/albumin ratio obtained at day 0. A minimum sample size of six mice per group was chosen to ensure 80% power to detect a 1.8 s.d. difference between two groups using a two-sided α = 0.05 t test. Comparison of M-spike reduction with different drug treatments relative to vehicle was done by unpaired two-sided t test with equal s.d. using GraphPad Prism (GraphPad Software). Comparison of Kaplan-Meier survival curves was performed by log-rank (Mantel-Cox) test using GraphPad Prism (GraphPad Software).
LCL161 clinical trial. Patient selection.
A one-stage design based on the binomial distribution required 25 patients to test the null hypothesis that the overall response rate was less than 10% versus an alternative hypothesis of greater than 30% with an α of 0.10 and power of 91%. Patients above 18 years of age seen at Mayo Clinic in Arizona, Rochester and Florida were included in the study if they had evidence of MM relapsed after previous treatment with an immunomodulatory agent and a proteasome inhibitor and a glucocorticoid, but fewer than five lines of prior therapy (with induction, transplant, consolidation and maintenance considered one line). Measurable disease in the form of serum monoclonal protein > = 1.0 g/dl, > 200 mg of monoclonal protein in the urine on 24 h electrophoresis or serum immunoglobulin free light chain (FLC) > = 10 mg/dl, along with abnormal serum immunoglobulin kappa to lambda light chain ratio was required for participation in the study. Patients were also required to have absolute neutrophil count ≥1,000/µl, platelet count ≥ 75,000/µl, hemoglobin ≥ 8g/dl, total bilirubin ≤1.5 mg/dl times the institutional upper limit of normal (ULN), AST ≤3× the institutional upper limit of normal (ULN), ALT ≤3x ULN, creatinine ≤2.5 mg/dl, ECOG performance status 0, 1 or 2, along with a negative pregnancy test. These criteria were specifically written to address clinical trial needs of patients with advanced disease, and those who are not normally eligible for standard clinical trials. Patients with other active malignancy or with other concurrent chemotherapy or radiotherapy, prior allogeneic transplantation or active autoimmune inflammatory condition were excluded from the study. The protocol was registered at clinicaltrials.gov under number NCT01955434 and was approved by the Mayo Clinic IRB. Informed consent was obtained from all study participants. A copy of the protocol is available in the supplementary material (Supplementary Data).
Patient treatment. Study treatment consisted of LCL161 18,00 mg administered orally weekly to the first 11 patients, and 1,200 mg to all subsequent patients. Patients were offered premedication with acetaminophen, ranitidine and diphenhydramine, but were not allowed to take a glucocorticoid stronger then prednisone 10 mg daily. Because of concerns for cytokine release syndrome (CRS), the first four doses were administered under close supervision in the clinic, and patients were provided with 8 mg of dexamethasone to take in the event of CRS occurrence. As part of the original clinical trial design, Cyclophosphamide 500 mg orally weekly was added for unconfirmed disease progression, or lack of response anytime after 8 weeks of therapy. Cyclophosphamide was discontinued after 1 year. The protocol allowed for treatment with LCL161 after discontinuing the cyclophosphamide at the discretion of the investigator until evidence of disease progression.
Evaluation of patient response and toxicity. Evaluation of response was performed every 4 weeks. Criteria for response and progression were based on International Myeloma Working Group Uniform Response Criteria for Multiple Myeloma. Response was evaluated over all cycles of treatment and required confirmation on two consecutive evaluations. When cyclophosphamide was added a new baseline disease measurement was established. Evaluation for toxicity was based on the National Cancer Institute CTCAE (v4.0). Toxicities were evaluated at every visit. The primary endpoint was response rate to single-agent LCL161; secondary endpoints included response rate following the addition of cyclophosphamide, toxicity, event-free and overall survival.
Results. 25 patients were enrolled between November 13, 2013 and February 16, 2016. Cyclophosphamide (for a maximum of 12 months) was added to 23 patients. Eleven patients withdrew from the study with stable disease, and ten withdrew with progressive disease. Two patients remain on treatment with single-agent LCL-161. The baseline characteristics are shown in Supplementary Table 1. In the phase 1 study, grade 3 to 4 CRS was the dose-limiting toxicity at doses of 1,800 mg, 2,100 mg and 3,000 mg, with symptoms of fatigue, flushing, rash, vomiting, diarrhea, fever and hypotension, the timing of which was concurrent with the rapid increase in cytokine levels (TNF, IL-8, IL-10, CCL2) lasting 24-96 h 16 . Whereas investigators in other subsequent studies of LCL161 elected to premedicate with dexamethasone, we decided to limit the use of dexamethasone in this study. After we noted that four of the first 11 patients experienced grade 2 CRS, we decided to reduce the starting dose of LCL161 to 1,200 mg for the remaining patients, and no further CRS was noted. The episodes of CRS were managed with close observation, antihistamines, dexamethasone and fluid support if needed. Other toxicities are listed in Supplementary Table 2. Gene-expression analysis. RNA-sequencing was performed starting from 1 µg of CD138-selected cells from BM using Illumina paired-ends with six samples per lane of a HiSeq 2000. Gene expression was summarized using transcripts per million (TPM) calculated using Salmon aligned to Ensembl gene files from human (hg19) and mouse (mm10). Expression threshold was determined by visual examination of the histogram of log2 TPM and was determined to be "0" for both the mouse and human samples based on bi-modal distribution of the data. In the human there were 19,016 protein-coding genes, with 8,443 expressed above the threshold in three of the five treated samples, with 2,082 having 1.1-fold higher expression following treatment with LCL161 in three of the five treated samples. In the mouse, the analysis was confined to mice transplanted with tumor Vk12598. There were 22,174 protein-coding genes, with 9,720 having expression above the threshold in all four Vk12598 samples, with 2,296 having 1.2-fold higher expression following treatment with LCL161 in all four Vk12598 samples. Of the genes in these two lists, 384 were common to the analyses from both human and mouse samples (Supplementary Table 3 ). These genes, ordered according to the fold change in mouse, and in human, were used for gene set enrichment analysis using HALLMARK genesets. The observed enrichment score (ES) of a gene set was generated using a runningsum statistic along the ranked differential expression genes, where ES is the maximum deviation from zero encountered in the random walk. A phenotypebased permutation test was performed to generate a null distribution of the ES, and the empirical, nominal P value of a gene set was calculated as the observed ES relative to this null distribution. The FASTQ files of the RNA-seq data were submitted to Sequence Read Archive under accession number SRP075564.
Antibodies. Antibodies were purchased from BD Biosciences, BioLegend, eBioscience or Antibodies online. B220 (RA3-6B2), CD138 (281-2), CD11b (M1/70), F4/80 (BM8), CD11c (N418), CD86 (GL1), CD40 (HM40-3), CD3 (17A2), CD4 (GK1.5), CD8 (53-6.7), CD44 (IM7), CD62L (MEL14), PD-1 (29F.1A12), PDL1 (10F.9G2 and 29E.2A3), CD47 (miap301), Calreticulin (RB21112), CD25 (PC61), FoxP3 (FKJ16S), INOS, IL-12/IL23p40 (C15.6) and IFN-γ (XMG1.2) were all used at 1:500 dilution, with the exception of anti-CD3 and anti-CD47 (1:100) and anti-calreticulin (1:50). Each of these antibody clones has been extensively validated by the sci-entific community and individual lots are quality-controlled by the manufacturers.
Intracellular cytokine staining.
For intracellular detection of cytokines on myeloid cells, cells were incubated with brefeldin A (BFA, BD Biosciences) for 4 h in mouse medium without further stimulation or treatment, stained for extracellular markers, fixed and permeabilized in Cytofix/Cytoperm (BD Biosciences), and stained with antibody against iNOS or IL-12p40. For intracellular staining of T lymphocytes, cells were stimulated with PMA (60 ng/ml) and ionomycin (1 ug/ml, both from Sigma-Aldrich) for 1 h before incubation with BFA for four additional hours.
Intracellular staining for FoxP3. After staining for surface antigens, cells were suspended in Fixation/Permeabilization reagent (eBioscience) for 18 h at 4 °C. Cells were then incubated with anti-FoxP3-PE antibody, washed in Permeabilization/Wash buffer (eBioscience), and analyzed.
Sample acquisition. Data were acquired on a five laser BD LSR Fortessa equipped with DIVA software (BD Biosciences) and analyzed with FlowJo software (Tree Star) after exclusion of cell doublets and dead cells. Statistical analysis was performed by unpaired Student's t test with equal s.d. using GraphPad Prism (GraphPad Software).
Generation of BM-derived MΦ (BMDM) and dendritic cells (BMDC)
. BM cells were collected by flushing out the two femurs and tibia with PBS and plated in DMEM/F12 supplemented with 10% FBS, penicillin and streptomycin and 20% of m-CSF rich L929 conditioned medium (obtained from growing L929 cells at confluence in DMEM/F12 +10% FBS). After 7 d, cells were harvested with a nonenzymatic cell-dissociation solution (Cellstripper, Corning) and evaluated by flow cytometry for the expression of CD11b and F4/80. To generate BMDC, BM cells were plated in RPMI1640 + 10% FBS + penicillin and streptomycin + Flt3 100 ng/ml (R&D System). After 5 d, half of the medium was replaced and BMDC were maintained for additional 4 d. Expression of CD11b and CD11c was evaluated by flow cytometry.
RT-PCR analysis. BMDM were stimulated for 9 h in DMEM/F12 complete medium alone, or supplemented with IFN-γ 10 ng/ml, LCL161 200 nM, or the combination. BMDC were stimulated or not with LCL161 200nM for 4 h. Cells were solubilized in Trizol (Invitrogen). RNA was extracted from Trizol, digested with RNase free DNase (Qiagen) and cleaned up on Purelink RNA mini-kit columns (Thermo Fisher Scientific). cDNA was retro-transcribed from 1 µg of RNA primed with random hexamers using Superscript-III (Invitrogen). 3 ng of equivalent cDNA were amplified in a qPCR (Taqman) assay on a Corbett Rotor Gene instrument (Corbett Life Science) for the following transcripts: TNF (IDT Assay Mm.PT.56a.12575861), IFN-β1 (IDT Assay Mm.PT.56a.30132453.g), IL-6 (IDT assay Mm.PT.56a.10005566), IL12b (SyBr green PCR using primers 5′-CCATCGTTTTGCTGGTGTCTCC and 5′-ATGGTCAGGGTCTTTCCAGAGC), IRF3 (SyBr green PCR using primers 5′-GATGGAGAGGTCCACAAGGA and 5′-GAGTGTAGCGTGGGGAGTGT), IRF7 (SyBr green PCR using primers 5′-CCTCTTGCTTCAGGTTCTGC and 5′-GCTGCATAGGGTTCCTCGTA). Relative gene expression was quantified with the 2 −∆∆C method, normalized to PolR2a housekeeping gene detected by SyBr green RT-PCR (5′-AGAAGCTGGTCCTTCGAATCC and 5′-TTG CTGATCTGCTCGATACCC). Data were collected from two independent culture experiments, where each sample was tested in triplicates.
Cytokine detection. Two femurs from each mouse were placed into a 0.5-ml microtube with a hole at the bottom after their kneecaps were removed. The tube was placed inside a 1.5-ml microtube, which was spun to obtained a BM cell pellet, which was suspended into 50-µl PBS, and spun again. The obtained BM supernatant was stored frozen at −80 °C until ready for analysis in duplicate with the Cytokine Mouse 20-Plex Panel for Luminex Platform (LMC0006, Thermo Fisher Scientific) according to manufacturer's instructions. Data were acquired on a Luminex200 system equipped with xPONENT 3.1 software (Thermo Fisher Scientific). Human BM plasma obtained from MM patients enrolled in the clinical trial at baseline and 3 or 4 weeks after LCL161 single-agent treatment was assayed in duplicate using the Cytokine Human 30-Plex Panel for Luminex Platform (LHC0003, Thermo Fisher Scientific). Similar analysis was performed on peripheral blood plasma from MM patients collected at baseline and four hours after LCL161 administration.
Phagocytosis assay.
In vitro generated BMDM were left untreated or stimulated overnight with IFN-γ 50 ng/ml, LCL161 200 nM or the combination, and then harvested with Cellstripper. 5 × 10 4 BMDMs were plated in a round-bottom, nontissue-culture-treated 96-well plate. Logarithmically growing Vk26963 lymphoma target cells, treated or not with LCL161 200 nM overnight, were labeled with CFSE (Molecular Probes) and 2.5 × 10 5 cells per well were added to the BMDM culture. The mixture of BMDM and target cells was harvested 2 h later, stained for viability with Live/Dead Blue, CD11b and F4/80 and evaluated on a flow cytometer for live, single CD11b + F4/80 + CFSE + BMDMs. In separate experiments, 15 million Vk26963 were left untreated or treated for 24 h in 10 ml of mouse medium with LCL161 200 nM, mouse IgG1 25 µg/ml, anti-IFNAR1 25 µg/ml or the combination. The conditioned medium was collected and used to stimulate BMDM overnight, in the presence of IFN-γ, to phagocytize untreated Vk26963 target cells.
Intra-vital two-photon imaging. Details of the surgical preparation for the mouse tibial BM imaging were described previously 65 . To generate tumors, 1e5 GFP + CD138 + Vk14451 MM cells were injected i.v. into C57BL/6 WT mice and allowed to engraft and grow for 2-4 weeks. To visualize MΦ in the BM, mice were injected with PE-conjugated anti-CD169 (SER-4 eBioscience) 16 h before imaging. For splenic imaging, spleens were surgically exposed, and immobilized as described previously 66 . To visualize red pulp MΦ, mice were injected with Texas red-labeled 10-kD dextran (Sigma-Aldrich) 16 h before imaging. Mice were imaged 4 h after drug treatment or without treatment. Time-lapse images were compiled and presented using Volocity (PerkinElmer) and After Effects (Adobe).
Analysis of in vivo phagocytosis. Quantification of phagocytic cells in GFP + myeloma cells was conducted by semi-automated protocols in velocity, to identify volume of GFP + myeloma and PE + phagocytes per field. Similar regions (with matching GFP + volume) were analyzed and compared for phagocyte volume with and without treatment. To measure phagocytosis, semi-automated detection of red phagocytes was conducted, and then using a standard threshold for GFP + cells, the frequency of phagocytosis was quantified as (number of double-positive GFP + PE + phagocytes)/(total number of PE + phagocytes × 100). To normalize between imaging fields with different distributions of myeloma and phagocytic cells, phagocytes were clustered into proximal and distal, based on a 5-µm distance from the edge of the nearest myeloma cell. Data were collected from treated and untreated mice from three or more independent imaging experiments, values were pooled, and means were compared by Mann-Whitney t-test.
